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Abstract
The maintenance of endothelial cell-cell junctions is vital for the control of blood vessel leakage and is known to be
important in the growth and maturation of new blood vessels during angiogenesis. Here we have investigated the role of a
tight junction molecule, Claudin14, in tumour blood vessel leakage, angiogenesis and tumour growth. Using syngeneic
tumour models our results showed that genetic ablation of Claudin14 was not sufficient to affect tumour blood vessel
morphology or function. However, and surprisingly, Claudin14-heterozygous mice displayed several blood vessel-related
phenotypes including: disruption of ZO-1-positive cell-cell junctions in tumour blood vessels; abnormal distribution of
basement membrane laminin around tumour blood vessels; increased intratumoural leakage and decreased intratumoural
hypoxia. Additionally, although total numbers of tumour blood vessels were increased in Claudin14-heterozygous mice, and
in VEGF-stimulated angiogenesis ex vivo, the number of lumenated vessels was not changed between genotypes and this
correlated with no difference in syngeneic tumour growth between wild-type, Claudin14-heterozygous and Claudin14-null
mice. Lastly, Claudin14-heterozygosity, but not complete deficiency, also enhanced endothelial cell proliferation
significantly. These data establish a new role for Claudin14 in the regulation of tumour blood vessel integrity and
angiogenesis that is evident only after the partial loss of this molecule in Claudin14-heterozyous mice but not in Claudin14-
null mice.
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Introduction
Blood vessel maturation, during angiogenesis, involves estab-
lishment of endothelial cell-cell contacts, deposition of an intact
basement membrane, lumen formation and the recruitment of
supporting cells [1–3]. The quality of tumour blood vessels differs
significantly from the normal vasculature. Their rapid formation
leads to increased vessel leakage, poorly controlled lumen
formation and discontinuous supporting cell association. Tumour
blood vessels are characteristically leaky, thus enhancing the
diffusion of oxygen and nutrients into the tumour mass, but their
chaotic organisation also results in regions of intratumoural
hypoxia and necrosis [4], [5].
Endothelial cell-cell junction integrity is a determinant of
vascular permeability. Tight junctions (TJs) in both epithelial and
endothelial cells consist of several protein families, including JAMs,
occludin and claudins [6]. TJs are signal transduction complexes
that communicate information from the environment to the cell
interior, regulating cell morphology, motility, gene expression,
signalling and crosstalk with non-TJ proteins [7]. The regulation
of TJ formation [8], [9] can impact upon several cellular processes,
including vascular permeability and cell proliferation [10], [11].
Some TJ protein families have endothelial cell-specific members
such as vascular endothelial junctional adhesion molecule (VE-
JAM, also known as JAM2 or JAM-B), and endothelial cell-
enriched molecules, for example Claudin5 (Cldn5) [12], [13].
Cldn5 is typically thought to be the major endothelial claudin
protein, but its expression has now also been noted in rat
pancreatic acinar cells, stomach and gut epithelia, and in human
immune cells [13–15]. It is known to be vital in maintaining the
integrity of the endothelial blood-brain barrier (BBB), since
knockout mice display size-selective loosening of the barrier [16].
Cldn5 expression appears to be dependent on the adhesion of
endothelial cells to the ECM via b1-integrin, and is controlled by
adherens junctions via VECAD, FoxO1 and b-catenin transcrip-
tional regulation [17–19].
Another claudin family member, Claudin14 (Cldn14), has been
identified in both epithelial and endothelial cell layers. Cldn14
mutations have been identified as a key cause of autosomal
recessive deafness [20], [21]. Additionally this molecule has been
found to be a regulator of kidney epithelial permeability [22].
However, the precise functions of Cldn14 in angiogenesis in vivo
and particularly in tumour angiogenesis are unknown.
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Here we describe that, surprisingly, homozygous loss of Cldn14
has little to no effect on tumour angiogenesis. However, in
Cldn14-heterozygous mice (with loss of only one copy of Cldn14)
we found the following major phenotypes: (1) disruption of cell-cell
junctions in tumour blood vessel; (2) abnormal tumour blood
vessel basement membrane organisation and reduced supporting
cell association; (3) increased intratumoural leakage and decreased
tumour hypoxia; (4) enhanced tumour angiogenesis but no
significant difference in the proportion of lumenated tumour
blood vessels; (5) no effect on syngeneic tumour growth and (5)
increased endothelial cell proliferation in vivo, ex vivo and in vitro.
In short our data establish that Cldn14 heterozygosity, but not
complete deficiency, can affect tumour blood vessel functionality
and describe a gene dosage effect of this molecule on angiogenic
processes.
Methods
Mice
All animals were used in accordance with UK Home Office
regulations and approved by the Queen Mary University of
London and Oxford University ethics committee. License 70/
7449.
Claudin14-null mice on a C57/bl6 genetic background [20]
were crossed with pure C57/bl6 (wild-type or WT) mice
purchased from Charles River to create heterozygous (Het)
progeny, from which new breeding pairs were set up to create
colonies of Cldn14 WT, Cldn14-heterozygous and Cldn14-null
mice. Genotyping was performed using the common primer:
Cldn14 common [59 - GGC TGC ATA ACC AGG ATA CTC -
39] with Cldn14 WT primer [59 - GTA CAG GCT GAA TGA
CTA CGT G - 39] for the wild-type allele (340 bp band) and
Cldn14 common with Cldn14 Mutant primer [59 - CAG CTC
ATT CCT CCC ACT CAT GAT C - 39] for the null allele (275
bp band) in two separate PCR reactions. Mice were born in
normal Mendelian ratios and male:female ratios, no obvious
adverse effects were observed, and proportionately decreased
Cldn14 mRNA levels were confirmed in kidneys and brains of
Cldn14-het and Cldn14-null animals, compared to wild-type
littermates (see Figure S1).
Subcutaneous syngeneic tumour models
Mouse tumour cell lines B16F10 melanoma (ATCCH Number:
CRL-6475 TM) and Lewis Lung Carcinoma (ATCCH Number:
CRL-1642 TM) cells were grown in DMEM (Gibco) supplemented
with 10% v/v FBS (EU-approved heat-inactivated fetal bovine
serum (PAA Laboratories, A15–104) and penicillin/streptomycin
(Gibco). Tumour cells were trypsinised and resuspended in PBS at
a concentration of 56106 cells ml21. 0.56106 tumour cells in
100 ml PBS were injected subcutaneously in the flank. Palpable
tumours were measured with callipers every other day and
bisected. Half of the tumour was snap-frozen for cryosectioning,
and the other half fixed in 4% formalin. Formalin-fixed tumours
were embedded in paraffin for sectioning.
Antibodies
Anti-endomucin 1:500 (Santa Cruz: V.7C7 sc-65495); anti-a-
Smooth Muscle Actin-Cy3 1:1000 (Sigma, C6198); anti-Pimoni-
dazole 1:10 (HPI, Inc. HP2-1000); Ki67 1:100 (Vector Labs,
VPK451), anti-ZO-1 1:100 (Invitrogen, 40–2200). PE-PECAM
1:500 (Biolegend, 102408), FITC-BS1 lectin (Sigma Isolectin B4,
L2895).
Hoechst leakage assay
10 minutes prior to sacrifice, tumour-bearing mice were injected
with 100 ml PE-PECAM antibody (undiluted, BioLegend:
102408). 1 minute before sacrifice, the same mice were injected
intravenously in the tail vein with 100 ml 4 mg/ml Hoechst dye
(Sigma bisBenzimide H33342 trihydrochloride, B2261), diluted in
ddH2O. Tumours were processed immediately after cervical
dislocation. 100 mm cryosections were thawed, rehydrated and
fixed for 10 minutes in 220uC methanol then mounted with
ProLong GoldTM with Antifade (Invitrogen, P36930). 100 mm Z-
stacks (stack interval 0.5 mm, 206magnification) were taken using
a Zeiss LSM 510 confocal microscope. LSM images were analysed
using ImageJ: red (PE-PECAM) and blue (Hoechst) pixel
intensities were obtained using colour thresholding to remove
background noise and Hoechst staining was quantified and
normalised to blood vessel density for each section to give Relative
Intensity values.
Pimonidazole detection of hypoxia
1 hour prior to sacrifice, tumour-bearing mice were injected
with 60 mg/kg pimonidazole hydrochloride (HypoxyprobeTM-1
HPI, Inc., diluted in ddH2O to a final concentration of 10 mg/ml)
intravenously via the tail vein [23]. Tumours were processed
immediately after cervical dislocation. 8 mm cryosections were
thawed, rehydrated and fixed for 10 minutes in 220uC acetone
then incubated with 1:10 anti-pimonidazole and 1:500 PE-
conjugated anti-PECAM antibodies to identify hypoxic areas
and blood vessels respectively. Sections were then washed and
mounted with ProLong GoldTM with Antifade (Invitrogen,
P36930). Images were taken with a Zeiss microscope and Axioplan
camera. Grids were used to divide the images into sectors and the
distance from PECAM-positive blood vessels to the closest
pimonidazole-positive (hypoxic) areas were measured in Adobe
Photoshop CS5. The average inverse values of these distances
were taken to give the hypoxic index.
Immunohistochemistry
FFPE 8 mm sections were processed as follows: (1) antigen
retrieval 2610 minutes boiling in citrate buffer (0.294% w/v Tri-
Sodium citrate (Fisher) in ddH2O, brought to pH 6 with acetic
acid). (2) Deparaffinising in xylene and ethanol solutions of
decreasing concentration. (3) Blocking: 30 minutes in 2% v/v Goat
serum, 1% w/v Bovine Serum Albumin, 0.1% v/v Triton X-100
in PBS. (4) Washing with 0.1% w/v Bovine Serum Albumin in
PBS. (5) Incubation with anti-endomucin primary antibody
(diluted in wash buffer) overnight at 4uC. (6) Washing in wash
buffer. (7) Incubation with 1:100 secondary antibodies (Invitrogen:
Alexa FluorH 488, with addition of a-SMA-Cy3 for pericytes). (8)
Final washing with PBS then ddH2O. (9) Mounting with
ProLongH Gold Antifade with DAPI (Invitrogen: P36931).
8 mm cryosections were processed for ZO-1 and PECAM
immunostaining as follows: 1) fixation with 220uC methanol for
10 minutes. 2) Blocking: 45 minutes in 5% w/v BSA, 0.1% v/v
Triton X-100 in PBS. 3) 36 PBS washes. 4) Incubation with
primary antibodies for 45 minutes at room temperature, diluted in
blocking buffer. 5) 36PBS washes. 6) Incubation with secondary
antibodies for 2 hours, diluted in blocking buffer. 7) 36 PBS
washes. 8) Final H2O wash. 9) Mounting with ProLongH Gold
Antifade with DAPI.
8 mm cryosections were processed for Ki67 immunostaining as
follows: 1) fixation in 220uC acetone for 10 minutes. 2)
Permeabilisation with 0.5% NP-40 for 10 minutes. 3) Blocking:
1 hour in 1% w/v BSA, 0.1% Triton X-100 in PBS. 4) Incubation
with primary antibody diluted in blocking buffer at 4uC overnight.
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5) Washing, secondary antibody incubation and mounting as in
steps 5–9 above.
Aortic Ring Assay
The aortic ring assay was performed as described in Baker et al.
2012 [24]. Briefly, thoracic aortae were taken from mice sacrificed
by cervical dislocation then cleaned and cut into 1 mm thick rings.
Rings were serum-starved overnight, embedded in a collagen-
OptiMEMH mixture and fed with OptiMEMH containing 2.5%
FBS (EU-approved heat-inactivated fetal bovine serum (PAA
Laboratories, A15–104) and 30 ng/ml VEGF or PBS as a control.
Endothelial microvessel sprouts were counted every other day
from days 5–9 until fixation of the explant cultures using 4%
formalin. Following fixation, the cultures were stained with FITC-
conjugated BS-1 Lectin (Sigma, L9381) and Cy3-conjugated a-
SMA antibody then mounted on slides using ProLong GoldTM
with Anti-fade and DAPI. A Zeiss AxioPlan microscope and
AxioVision software were used for imaging. For the Invitrogen
ClickITH EdU proliferation assay [24]; aortic rings are treated
with EdU prior to fixation as previously described and then
stained with Alexa FluorH 488 secondary antibody as according to
the manufacturers’ protocol, using reduced reagent volumes.
Rings are co-stained with TRITC-conjugated BS1-lectin (Sigma,
L5264).
Primary endothelial cell culture
Primary mouse endothelial cells were purified and cultured
from mouse lung as described in Reynolds and Hodivala-Dilke,
2006 [25]. Briefly, mouse lungs were dissected, rinsed in F-12 +
GlutaMAXTM (Gibco) medium, 70% ethanol then MLEC
medium (1:1 mixture of F-12 and low-glucose DMEM (DMEM
+ GlutaMAXTM +1 g/L D-Glucose + Pyruvate, Gibco) supple-
mented with 20% v/v FBS, 100 mg L21 heparin (Sigma), 1% v/v
1006glutamine (GlutaMAXTM 1006, Gibco 35050), Endothelial
Growth Supplement (AbD Serotec, 4110–5004) and 1% v/v 1006
penicillin/streptomycin (Gibco)). Lungs were then minced and
digested in 0.1% Type I Collagenase (Gibco, 17100–017), passed
through a 70 mm cell strainer (BD Falcon) and the resulting single-
cell suspension plated on pre-coated plastic. Macrophages were
removed from the resulting cultures using rat anti-mouse FCcII/
III (Pharmingen) antibody and sheep anti-rat IgG-coated magnetic
bead sorting (Dynal). Endothelial cell cultures were enriched by
positive sort, using two rounds of anti-CD102 (ICAM2) antibody
(Pharmingen) and Dynal anti-rat magnetic beads.
Results
Cldn14 heterozygosity, but not deficiency, destabilises
tumour blood vessel morphology
It is conceivable that Cldn14 could affect vascular integrity,
since it is a component of tight junctions. To test the requirement
for Cldn14 in the maintenance of vascular integrity and in
angiogenic processes in vivo, we used a Cldn14 genetic ablation
approach. Cldn14-heterozygous (Cldn14-het) mice were inter-
crossed to produce wild-type (WT), Cldn14-het and Cldn-14 null
progeny. No effects on Mendelian ratios or male:female ratios
were observed in litters (Figure S1 A–C). qPCR analysis
confirmed that levels in Cldn14-het organs were approximately
half those detected in WT mice, whilst Cldn14 transcript was
undetectable in Cldn14-nulls (Figure S1 D). Due to the lack of
reliable reagents, we were not able to test whether Cldn14 is
expressed differentially in quiescent and angiogenic blood vessels in
vivo.
Given that Cldn14 is a tight junction protein, we first asked
whether deletion of Cldn14 could affect tumour endothelial cell-
cell junction organisation. Wild-type (WT), Cldn14 heterozygous
(Cldn14-het) and Cldn14-null mice were injected subcutaneously
with 0.56106 B16F10 melanoma cells. At 10 days post tumour cell
inoculation the tumours were snap-frozen and cryosections double
immunostained for the tight junction marker ZO-1 and the
endothelial cell marker PECAM. ZO-1 staining was confined to a
continuous pattern of expression at endothelial cell-cell junctions
in tumours from both WT and Cldn14-null animals, indicating
that Cldn14-deletion was not sufficient to affect the organisation of
ZO-1 at cell-cell junctions. In contrast, and surprisingly, a
discontinuous staining pattern of ZO-1 was observed in the
majority of Cldn14-het tumour blood vessels (Figure 1A, B). This
suggests that ZO-1 localisation to endothelial tight junctions is
affected by partial but not total loss of Cldn14 in blood vessels and
that this may contribute to the functionality of these vessels.
Given that extracellular matrix deposition and maintenance are
crucial steps in the maturation of tumour blood vessels, we next
asked if the distribution of laminin within the blood vessel
basement membrane was affected by changes in stromal Cldn14
levels. Tumour sections were double immunostained for PECAM
and laminin and observations showed that the pattern of laminin
deposition was proximate to the blood vessel wall in sections from
WT and Cldn14-null mice, indicating, again that Cldn14
deficiency was not sufficient to affect this process. In contrast, a
high frequency of disorganised laminin deposition around blood
vessels, with a ‘shorelining’ pattern, was observed in sections from
tumours grown in Cldn14-het mice (Figure 1C, D). This result
showed that the organisation of the basement membrane might be
affected by partial loss of Cldn14.
Blood vessel stabilisation is a consequence not only of basement
membrane deposition, but also the association of supporting a-
SMA-positive cells [26], [27]. To assess this, tumour sections were
co-stained for the differentiated pericyte cell marker a-SMA and
for endomucin. Results showed that the proportion of blood
vessels with a-SMA-positive pericyte association was reduced
significantly in tumours grown in Cldn14-het mice (Figure 1E,
F).
Stromal Claudin14-heterozygosity enhances tumour
blood vessel Hoechst leakage and decreases tumour
hypoxia
Considering the possible destabilisation of tumour blood vessels
in Cldn14-het animals, we sought to investigate whether loss of
Cldn14 affected the leakage of tumour blood vessels. WT, Cldn14-
het and Cldn14-null mice were injected subcutaneously with
0.56106 B16F10 melanoma or Lewis Lung Carcinoma (LLC)
cells. Intravenous injection of anti-PECAM (PE-PECAM) anti-
body and Hoechst dye into tumour-burdened mice revealed no
significant difference in Hoechst leakage from tumour vessels
between WT and Cldn14-null tumour-bearing mice relative to
PE-PECAM signal. However, a significant increase in Hoechst
leakage was observed in Cldn14-het mice when compared with
either WT or Cldn14-null mice (Figure 2A and B).
These results were corroborated when we examined the relative
levels of tumour hypoxia. Tail vein injections of pimonidazole
HypoxyprobeTM (HPI, Inc.) into tumour-bearing WT, Cldn14-het
and Cldn14-null mice showed that the relative levels of tumour
hypoxia were similar between WT and Cldn14-null mice
(Figure 2C, D). In contrast, hypoxic levels were found to be
significantly lower in both B16F10 and LLC tumours grown in
Cldn14-het mice when compared with controls (Figure 2C, D).
Claudin 14 and Vascular Leakage
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Figure 1. Cldn14 heterozygosity destabilises tumour blood vessels. B16F10 tumours were grown for 10 days in WT, Cldn14-het and Cldn14-
null mice and midline sections from size-matched tumours were analysed for blood vessel stabilisation by immunostaining for the tight junction
component ZO-1, basement membrane laminin, and pericyte coverage using an anti-aSMA antibody. (A) The tight junction adapter protein ZO-1
staining pattern was observed at cell-cell borders in PECAM-positive tumour blood vessels. A higher proportion of blood vessels exhibited a disrupted
ZO-1 staining pattern in Cldn14-het tumour sections, compared to tumours from WT and Cldn14-null mice. (B) Representative images of ZO-1
staining and the endothelial cell marker PECAM, with nuclei DAPI-counterstained. Inserts show higher magnification of ZO-1 at cell-cell junctions.
Scale bars: main panels = 50 mm, insets = 10 mm. (C) The AxioVision software linear measuring tool was used to analyse the spread (in mm) of laminin
surrounding PECAM-positive blood vessels in immunostained tumour sections. Laminin expression was close to blood vessel walls in tumours from
WT and Cldn14-null mice but disorganised around tumour blood vessels in Cldn14-het mice; a ‘‘shorelining’’ effect of laminin deposition was evident
in these sections. (D) Representative images of tumour cryosections immunostained for basement membrane laminin and the endothelial cell marker
PECAM, with nuclei DAPI-counterstained. White brackets indicate the spread of laminin staining radiating from PECAM-positive vessels and
demonstrates the quantification method. (E) a-Smooth Muscle Actin (aSMA) antibody conjugated to Cy3 fluorescent dye was used to label
supporting cells (pericytes) around endomucin-labelled blood vessels in midline tumour sections. The percentage of aSMA-positive vessels was
quantified. (F) Representative images of endomucin and aSMA double-stained tumour sections. Arrows, aSMA-negative vessels. Scale bar 50 mm.
N=4–6 tumours per genotype. Bar charts represent means 6 SEM. * P,0.05, *** P,0.001.
doi:10.1371/journal.pone.0062516.g001
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These data suggest that loss of one Cldn14 allele within the
stromal compartment is sufficient to enhance tumour blood vessel
leakage and decrease tumour hypoxia, but that complete Cldn14
deficiency does not affect these processes.
Stromal Cldn14-heterozygosity does not affect tumour
growth rates
The changes observed in tumour blood vessel leakage and
hypoxia may have been indicative of changes in tumour growth in
Cldn14-het mice. However, analysis of luciferase-tagged B16 and
LLC tumour growth rates demonstrated no significant differences
between any of the genotypes (Figure 3A–C). The lack of change
in tumour growth corresponded with no significant differences in
tumour cell proliferation in any of the genotypes (Figure 3D, E).
Thus, despite the apparent defects in the tumour blood vessel
morphology in Cldn14-het mice, no effect on tumour growth was
apparent.
Cldn14-heterozygous mice have increased tumour blood
vessel density, but show no difference in the number of
lumenated tumour blood vessels
Since tumour blood vessels appeared disrupted in Cldn14-het
mice, but tumour size was not affected, we then examined the
numbers of blood vessels in midline sections of size-matched
tumours grown in WT, Cldn14-Het and Cldn-14 null mice.
Surprisingly, blood vessel densities across midline tumour sections
were found to be elevated in tumours grown in Cldn14-het mice
when compared with WT and Cldn14-nulls (Figure 4A). In
contrast, total blood vessel density was comparable between all
genotypes in unchallenged skin suggesting that the change in
tumour blood vessel density was induced specifically in the tumour
environment (Figure S2). The apparent lack of correlation
between tumour size and blood vessel density suggested that the
functionality of the vessels in tumours grown in Cldn14-het mice
might have been affected. Tumour blood vessel functionality is
heterogeneous like the tumour mass itself, including those that are
functional (lumenated), and those that are not (closed). Analysis of
endomucin-stained tumour sections showed that the percentage of
closed vessels was elevated in Cldn14-het tumour sections
(Figure 4B), while lumenated vessel density was unchanged
between tumours grown in WT, Cldn14-het or Cldn14-null mice
(Figure 4C). Thus the lack of differences in lumenated blood
vessels between genotypes correlates with the similar tumour
growth rates in WT, Cldn14-het and Cldn14-null mice.
To examine further the effect of Cldn14-heterozygosity on
angiogenic processes, the ex vivo aortic ring assay was used [24].
Aortic rings isolated from WT, Cldn14-het and Cldn14-null mice
were embedded in collagen and treated with the pro-angiogenic
factor, VEGF or PBS as a negative control. In the absence of
VEGF microvessel outgrowth was minimal and the same across all
genotypes (Figure 5A). However, VEGF stimulated an increase in
Figure 2. Heterozygosity for Cldn14 increases tumour blood
vessel leakage and decreases intratumoural hypoxia. Wild-type,
Cldn14-heterozygous and Cldn14-null mice were injected subcutane-
ously in the flank with 0.56106 B16F10 melanoma or Lewis Lung
Carcinoma (LLC) cells. (A) At 10 days post inoculation, PE-conjugated
anti-PECAM antibody and Hoechst dye were injected via the tail vein
prior to sacrifice. Midline sections (100 mm) of snap-frozen tumours
were fixed, mounted and imaged using a Zeiss LSM 510 confocal
microscope. The extent of Hoechst leakage was measured in z-stacks
using ImageJ. Bars show mean Hoechst leakage relative to PECAM
signal 6 SEM. Blood vessel leakage is increased significantly in Cldn14-
het mice when compared with WT and Cldn14-null mice. (B)
Representative images of Hoechst (blue) and PECAM (red) detection.
(C) Tumour-bearing mice from each genotype were injected with
pimonidazole prior to sacrifice to measure hypoxic areas within the
tumour. 8 mm tumour cryosections were then double stained with anti-
pimonidazole antibody (green) to highlight hypoxic areas and anti-
PECAM antibody to identify blood vessels. The hypoxic index was
quantified relative to PECAM staining using image J software. Bars
represent mean relative hypoxic index 6 SEM. (D) Representative
images of pimonidazole detection and PECAM-positive blood vessels in
tumour sections. Arrows, blood vessels; Asterisks, pimonidazole-positive
staining. Scale bars: A 50 mm; D 200 mm. N= 4 tumours per genotype.
NSD: not statistically different, * P,0.05, ** P,0.01, *** P,0.001,
{ P= 0.09.
doi:10.1371/journal.pone.0062516.g002
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microvessel outgrowth in both WT and Cldn14-null aortic rings
and this was enhanced significantly in Cldn14-het aortic rings
(Figure 5A, C). Moreover, microvessels were also significantly
longer in Cldn14-het aortic ring assays when compared with WT
or Cldn14-null tests as determined by BS1 lectin staining
(Figure 5B, C). Taken together, the enhanced total tumour
blood vessel density counts in vivo and increased microvessel
sprouting ex vivo in Cldn14-hets indicate that partial, but not
complete, loss of Cldn14 is sufficient to enhance angiogenic
responses, but with compromised functionality.
Claudin14 heterozygosity increases endothelial cell
proliferation
Since enhanced angiogenic responses may reflect an increase in
endothelial proliferation we hypothesized that Cldn14-hetrozyg-
osity may elevate these processes. To test this, we first measured
proliferation of endothelial cells in tumours in vivo (Figure 6A, B),
ex vivo explants (Figure 6C, D) and cultured primary microvas-
cular endothelial cells from the lungs (Figure 6E, F). Data
revealed that proliferation was indeed enhanced in vivo, ex vivo and
in vitro in Cldn14-het endothelial cells when compared to both WT
and Cldn14-nulls (Figure 6). Enhanced angiogenesis may also
reflect changes in endothelial migration. We therefore also
analysed the ability of endothelial cells, isolated from each
genotype, to migrate in a VEGF gradient [28]. Time-lapse and
cell tracking analysis revealed a small decrease in the speed and
persistence of cell movement of Cldn14-null cells compared to
both WT and Cldn14-het cells (Figure S3).
These combined results demonstrate a role for the tight junction
protein Cldn14 in maintenance of tumour blood vessel integrity
and angiogenesis that was previously unknown. Importantly this
effect is realised not by the total genetic ablation of Cldn14 but in
its partial expression within the stromal microenvironment.
Discussion
The consequences of changes in Cldn14 expression levels on
tumour blood vessel fragility and angiogenesis have not been
addressed previously. Here we have shown that Cldn14 hetero-
zygosity, but not total deficiency, induces destabilisation of tumour
blood vessels, which correlates with enhanced vessel leakage and
decreased tumour hypoxia without affecting tumour growth.
Several papers have described how loss off cell-cell junction
function can enhance blood vessel leakage [29–32]. For example,
genetic ablation of VECAD and endothelial-specific deletion of
the cytoplasmic associated signalling molecule b-catenin have
reported a decrease vascular integrity, but most of these studies
have been confined to phenotypes observed in null mutant mice
Figure 3. Stromal Cldn14 heterozygosity does not affect tumour size or tumour cell proliferation.Wild-type and Cldn14-het and Cldn14-
null mice were injected subcutaneously with 0.56106 B16F10 melanoma or Lewis Lung Carcinoma (LLC) cells. (A and B) Tumour size was measured
every two days for up to 13 days. No difference in B16 or LLC tumour growth rate was observed between the genotypes. (C) Representative images
of B16 and LLC endpoint tumours from each genotype. N= 12–17 mice per tumour type per genotype. (D) Tumour cryosections were
immunostained for the proliferation marker Ki67 and the endothelial marker PECAM, with a DAPI nuclear stain. The percentage of Ki67-positive/
PECAM-negative tumour cells was counted. Bars show mean 6 SEM. (E) Representative images of Ki67-stained tumour sections. Scale bar 50 mm.
NSD: no significant difference.
doi:10.1371/journal.pone.0062516.g003
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Figure 4. Cldn14-heterozygous mice have increased tumour blood vessel density, but show no difference in the number of
lumenated tumour blood vessels. Wild-type and Cldn14-het and Cldn14-null mice were injected subcutaneously with 0.56106 B16F10
melanoma cells. Whole midline sections of frozen 13 day old tumours were fixed and stained with anti-endomucin antibody. (A) The total number of
blood vessels was counted across entire tumour sections and divided by the section area to give total mean blood vessel density for each genotype.
(B) Graph showing the percentage of total blood vessels that are closed in tumour sections. (C) Graph showing mean numbers of lumenated vessels
per mm2 of midline tumour section. (D) Representative images of endomucin-positive vessels in all genotypes Arrows, lumenated vessels;
arrowheads, non-lumenated vessels. Scale bar 50 mm. N=6 mice per genotype. For all graphs, bars show means 6 SEM. NSD: no significant
difference. * P,0.05.
Figure 5. Cldn14 heterozygosity increases VEGF-stimulated aortic ring microvessel sprouting and sprout length. A. Quantitation of
wild-type, Cldn14-heterozygous and Cldn14-null VEGF-stimulated aortic ring microvessel sprouting at 9 days in culture. PBS was used as a negative
control. VEGF-stimulated microvessel numbers were increased significantly in Cldn14-het samples when compared with similarly treated WT and
Cldn14 –null samples. B. Quantification of microvessel sprout length in using the ImageJ line tool on scaled images. N = 25–91 rings per genotype.
VEGF-stimulated microvessel length was increased significantly in Cldn14-het samples when compared with similarly treated WT and Cldn14-null
samples. C. Representative images of VEGF-treated BS1 lectin-stained aortic rings fixed and stained after 9 days in culture. Arrows, endothelial
microvessel sprouts. Scale bar 500 mm. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0062516.g005
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[29], [30]. It may be that the lack of angiogenic phenotypes in the
Cldn14-null mice is due to be due to molecular compensation, for
example by other claudin family members expressed in tumour
endothelial cells. Given that Cldn5 is an endothelial cell claudin
[13], [15], [16], we tested for differences in Cldn5 mRNA levels in
Cldn14-WT, Cldn14-het and Cldn14-null mouse kidney and
brain samples by qPCR. We found no significant differences in the
levels of Cldn5 message between the genotypes (data not shown)
suggesting that Cldn5 compensation may not be the cause of the
lack of Cldn14-null phenotypes. However, there may still be
differences in protein levels in the tumour context that we were
unable to identify in this study. The details of the mechanism by
which this hypothesised compensation occurs is yet to be
uncovered, but represents an important future goal for under-
standing potential co-regulation and crosstalk between levels of cell
adhesion molecules during angiogenesis.
Our observations that Cldn14 heterozygosity, but not total
deficiency, can cause: decreased endothelial cell-cell junctional
organisation; poor blood vessel basement membrane distribution;
and reduced supporting cell coverage, all describe how more
subtle changes in endothelial cell-cell junctions can dramatically
affect vascular function.
Claudins have been described to signal in co-ordination with
b1-integrins. Genetic ablation of the a3-integrin subunit results in
a basement membrane defect in which components of the
basement membrane, such as laminin, show a disorganised
Figure 6. Cldn14 gene copy number affects endothelial cell proliferation in vivo, ex vivo and in vitro. (A) Percentages of Ki67-positive
endothelial cells were counted in cryosections of 13-day B16F10 tumours from WT, Cldn14-het and Cldn14-null mice co-stained with PECAM.
Endothelial cell proliferation was enhanced significantly in Cldn14-het mice. (B) Representative images of tumour sections in each genotype. Arrows,
Ki67-positive endothelial cell nuclei. Scale bar 25 mm. (C) Proliferating cells in VEGF-stimulated wild-type, Cldn14-het and Cldn14-null collagen-
embedded aortic explants were detected by EdU incorporation. The number of proliferating (EdU-positive) nuclei, counterstained with DAPI, was
divided by the total number of cell nuclei also BS1-lectin positive to give % proliferating endothelial cells in VEGF-treated aortic rings. Bars show
mean % of proliferating cells 6 SEM. n = 6–8 rings per genotype, 513–717 nuclei per genotype. (D) Representative images of VEGF-stimulated WT,
Cldn14-het and Cldn14-null microvessels from aortic ring explants stained for EdU and BS1 lectin. Scale bar 50 mm. (E) WT, Cldn14-het and Cldn14-
null primary endothelial cells were examined for EdU incorporation in the presence of 30 ng/ml VEGF. Cells were counterstained with DAPI and the
number of EdU-positive cells recorded for each genotype. Bars show mean % EdU-positive cells 6 SEM. N= 1217–3464 nuclei per genotype, 3 mice
per genotype. (F) Representative images of primary endothelial cells in culture. Scale bar 50 mm. Arrows, EdU-positive nuclei. NSD: no significant
difference. * P,0.05, *** P,0.001.
doi:10.1371/journal.pone.0062516.g006
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expression pattern and a ‘shorelining effect’ [33] that is strikingly
similar to that observed in the tumour blood vessels of Cldn14-het
mice. In future studies, it would of interest to examine the effect of
Cldn14-heterozygosity on a3b1-integrin expression and function
since this may explain part of the phenotype observed here. This
disruption of the basement membrane organisation may be the
cause of the decreased supporting cell coverage in Cldn14-het
tumour blood vessels. This notion is corroborated by previously
published work in which mice lacking the laminin a4 chain
displayed reduced pericyte recruitment to blood vessels [34].
Alternatively, the reduced pericyte coverage to Cldn14-het blood
vessels could simply reflect a loss of cell-cell adhesion, either a
knock-on effect of the decreased association between endothelial
cells that subsequently affects pericyte adhesion, or even between
endothelial cells and pericytes directly. In line with this idea, it has
been reported that, in human glioblastoma multiforme patients,
expression of claudins 1 and 5 is drastically reduced, together with
an increase in blood vessel fragility and decreased a-SMA-positive
differentiated pericyte coverage [35].
In addition, the increased tumour vascular fragility that we have
observed in Cldn14-het mice is associated with enhanced
endothelial proliferation in vivo, ex vivo and in endothelial cell
cultures in vitro. It is tempting to speculate that this gives rise to an
actual increase in total blood vessel numbers in Cldn14-het mice
even if a significant proportion of these vessels are not properly
lumenated. Cldn14 has previously been found to be downregu-
lated in proliferating endothelial cells [36]. Our results may
expand upon these findings, showing that partial loss of Cldn14
could be responsible for enhanced endothelial proliferation. It is
known that tight junctions influence cellular proliferation by
downstream signalling pathways including the transcription factor
ZONAB, which can shuttle to the nucleus and interact with Cdk4.
This pathway in turn regulates cyclin D1 and PCNA to influence
G1 to S phase cell cycle progression [11], [37]. It may be that the
partial loss of Cldn14 alters the available nuclear pool of ZONAB
and affects cellular proliferation in this way; further studies of
ZONAB subcellular localisation and proliferation markers in
Cldn14-het endothelial cells could explore this possibility. How
does this relate to the loss of lumen formation in a significant
proportion of Cldn14-het tumour blood vessels? Reports have
shown that lumen formation is caused by apoptosis [38]. It is
therefore conceivable that an imbalance of proliferation and
apoptosis in Cldn14-het endothelial cells is the reason for the
reduced lumen formation in Cldn14-het mice. Our results indicate
that since total loss of Cldn14 is unlikely to be physiologically
relevant understanding the effects of partial loss of Cldn14 in the
context of the endothelium, using a gene dosage strategy may be
important in understanding the regulation of its biological
functions.
Our work may also have some clinical relevance. It is difficult to
prove that any pharmacological inhibitor has a complete blocking
effect when used therapeutically, therefore understanding how
partial loss, or blockade, may affect biological outcome also
becomes of interest. To our knowledge Cldn14 inhibitors have not
yet been tested for their effect on blood vessels, if indeed they are
available, but if they were it is conceivable that partial
pharmacological inhibition could promote some or all of the
phenotypes that we have described in the Cldn14-het mice. For
example, partial Cldn14 inhibition may decrease intratumoural
hypoxia and pericyte association with blood vessels. Others have
shown that decreased tumour hypoxia can sensitise tumour cells to
chemotherapy and radiotherapy treatments [39–41] and that
decreased pericyte coverage can increase sensitivity to anti-
vascular agents [42], [43]. Thus, is it possible that combining
anti-Cldn14 strategies with chemotherapy or anti-VEGF therapies
may provide benefits [44]. All of these are certainly interesting
ideas for future studies but beyond the scope of the report
presented here.
In short, our findings highlight new roles for Cldn14 in vascular
function and angiogenesis that are relevant directly to its levels of
expression and not simply the presence of absence of this
molecule.
Supporting Information
Figure S1 Genotyping and colony statistics for Cldn14
mice. (A) A representative agarose gel is shown with separate
PCR reactions, for Cldn14 WT (lanes 1, 3 and 5) and Cldn14-null
alleles (lanes 2, 4 and 6). PCR products identify wild-type (lanes 1
and 2), Cldn14-heterozygous (lanes 3 and 4) and Cldn14-null
(lanes 5 and 6) DNA samples. (B) The bar chart represent the
numbers and of WT, Cldn14-Het and Cldn14-null mice at
weaning from Cldn14 heterozygous breeding pairs. All genotypes
developed at expected Mendelian ratios. N= 25 litters and 189
mice. (C) Proportion of male:female pups in the Cldn14 colony is
normal and as expected. (D) qPCR analysis Cldn14 transcript
expression from WT, Cldn14-het and Cldn14-null tissues. Cldn14
mRNA levels are shown relative to b-actin (ACTB) controls, with
approximately half as much transcript detected in Cldn14-het
organs and undetectable levels in Cldn14-nulls when compared
with WT controls. Please see Text S1 for qPCR method details.
Bars show relative transcript levels 6 SEM. N=3 separate tissue
samples per genotype.
(TIF)
Figure S2 Vessel density in unchallenged skin is
unaffected by the Cldn14 genotype. Blood vessel density
was quantified in WT, Cldn14-het and Cldn14-null transverse skin
sections, taken from non-tumour burdened mice. Values are given
as mean number of dermal blood vessels per mm2 of dermal
section. Bars represent mean 6 SEM. NSD: no significant
difference.
(TIF)
Figure S3 Migration of WT, Cldn14-het and Cldn14-null
endothelial cells. Primary endothelial cells were cultured from
WT, Cldn14-heterozygous and Cldn14-null mouse lungs. Cells
were plated on coverslips and inverted over Dunn chamber slides
filled with serum-free growth medium and medium containing
100 ng/ml VEGF to stimulate cell movement. Cells were
photographed at 10-minute intervals over 16 hours to create movie
files for cell tracking with Andor software and analysis using
Mathematica software. (A) Raw cell tracking data with all cell
starting positions at a single point of origin. (B) Speed of cellular
movement (mm/min). (C) Persistence of cell movement (tendency of
cells to move directionally without deviation). Please see Text S1
for Dunn Chamber Chemotaxis assay method details. Bar charts
show means 6 SEM. N=12–20 fields per genotype, 280–348 cells
per genotype, 2 independent experiments. * P,0.05 ** P,0.01.
(TIF)
Text S1 Supplementary methods. Details of methods used
to produce data for Figure S1 and Figure S2: organ harvesting,
RNA extraction, qPCR and Dunn Chamber Chemotaxis assays.
(DOC)
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